Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors

This study is testing whether analyzing DNA fragments floating in the blood (called cell-free DNA or cfDNA) can help detect and distinguish between different types of pancreatic tumors earlier and more accurately — without invasive biopsy. **You may be eligible if...** - You are 18 or older - You have been diagnosed with one of three types of solid pancreatic tumors: a non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer), or solid pseudopapillary tumor - You have not received any anti-cancer treatment before your surgery - You are scheduled to have surgery to remove the tumor **You may NOT be eligible if...** - You have received chemotherapy, radiation, or other anti-cancer treatments before surgery - You have another active cancer at the same time - You are unable or unwilling to provide consent or a blood sample Talk to your doctor to see if this trial is right for you.